medi acquires CircAid

WHITSETT, N.C., Aug. 8, 2012—medi, headquartered in Bayreuth, Germany, and a leading global player in the health-care market, has acquired San Diego-based CircAid, expanding its compression therapy division to offer compression therapy garments to help patients throughout the world feel better every day.

With over 320 product brands and patents, 17 international group companies and direct export to over 100 countries, medi has been a leader in the management and treatment of conditions related to venous disease, lymphedema, musculoskeletal injury, rehabilitation and lower extremity amputation.

CircAid specializes in compression garments for the treatment of lymphedema, venous disease and other edema-related disorders. CircAid’s focus has always been to ensure that patients are enabled to live and maintain independent lifestyles.

Dr. Michael Weihermueller, managing director of medi Global, is committed to the continued development of innovative products and therapies that fulfill a fundamental social responsibility toward improving the quality of life for the users of medi products. “Our strategic goal is to increase our involvement in patient treatment by facilitating better patient results and overall management. The CircAid product offering fits well within our existing infrastructure and capabilities, enabling patient engagement earlier in the treatment of venous and lymphatic disease to encourage better outcomes.”

Sandra Shaw, CEO and founder of CircAid, believes this merger will benefit all involved. “The synergy of the companies coming together will provide the necessary resources to enhance product development and increase market visibility, all with patient care in mind.” Shaw will remain with the company for a minimum of two years to assist with the transition.

CircAid’s manufacturing and logistical operations will remain in San Diego. medi will incorporate CircAid’s sales and marketing activities within its medi U.S. headquarters in North Carolina. Learn more at www.mediusa.com.